At PEAR, we are focused on the development of prescription digital therapeutics and drug/software combinations to treat diseases with high unmet medical need.
PEAR is a fully integrated, prescription digital therapeutics company
We are developing software-based, prescription interventions in compliance with FDA requirements for Software as a Medical Device (SaMD) products, testing the efficacy of these interventions in randomized clinical trials, leveraging clinical trial data to file for FDA approval and clearance, and commercializing approved products. Our goal is to provide safe and efficacious products for patients, supportive engagement and tracking tools for clinicians, and cost-effective solutions for payers.
Prescription digital therapeutics to treat unmet need
PEAR has developed a pipeline of clinically validated, prescription digital therapeutics we call eFormulations™.
Our lead program, reSET®, targets substance use disorder
Targeting opiate dependence, reSET-O™ is being developed as a medication/software combination
Our pipeline includes the first clinically-validated digital therapeutic for treating schizophrenia
reCALL is a Virtual Reality prescription digital therapeutic
Pear is also working on Generalized Anxiety Disorder (GAD), post-surgical pain, Major Depressive Disorder (MDD), and insomnia, among other indications.
PEAR’s lead products, reSET® and reSET-O™ have been evaluated in 6 randomized clinical trials involving over 1500 patients.
In a clinical trial involving patients diagnosed with Substance Use Disorder (SUD), reSET® significantly enhanced both abstinence rates and retention in treatment compared to intensive, in-office therapy.
reSET-O™ has successfully completed pivotal studies for the treatment of Opiate Use Disorder (OUD) when used in combination with Buprenorphine.
Thrive™ has been examined in three clinical studies involving 1,279 patients. Efficacy has been demonstrated as assessed by PANSS (the aggregate approvable endpoint for schizophrenia therapies) and patient engagement has been demonstrated beyond six months.